Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 76 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent GlioblastomaCompletedNCT02866747Phase 1/2
• Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer PatientsCompletedNCT02866383Phase 2
• Atezolizumab in Treating Patients With Cancer Following Adoptive Cell TransferActive, not recruitingNCT02862275Phase 1
• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Active, not recruitingNCT02861573Phase 1/2
• Trial Of Pembrolizumab And NintedanibCompletedNCT02856425Phase 1
• Special Combination of BBI608 and PembrolizumabTerminatedNCT02851004Phase 1/2
• Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter SyndromeActive, not recruitingNCT02846623Phase 2
• Single Agent and Combined Inhibition After Allogeneic Stem Cell TransplantTerminatedNCT02846376Phase 1
• Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the BladderActive, not recruitingNCT02845323Phase 2
• Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid TumorsStatus unknownNCT02836834Phase 1
• Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid TumorsCompletedNCT02836795Phase 1
• Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2
• Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade GliomasCompletedNCT02829931Phase 1
• Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid TumorsCompletedNCT02827968Phase 1
• Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial CancerCompletedNCT02826564Phase 1
• A Study to Assess the Pharmacokinetics, Efficacy, and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy in Chinese Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02825940Phase 1
• X4P-001 and Pembrolizumab in Patients With Advanced MelanomaCompletedNCT02823405Phase 1
• MEDI4736 Combinations in Metastatic Renal Cell CarcinomaCompletedNCT02819596Phase 2
• Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced MelanomaTerminatedNCT02818023Phase 1
• A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)Active, not recruitingNCT02817633Phase 1
• Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic MelanomaCompletedNCT02816021Phase 2
• Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway InhibitorCompletedNCT02814669Phase 1
• A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing ChemotherapyCompletedNCT02813785Phase 3
• A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and LymphomasCompletedNCT02812875Phase 1
• Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/AmplificationWithdrawnNCT02812693Phase 1/2
• Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02812667Phase 1
• Ipilimumab for Head and Neck Cancer PatientsActive, not recruitingNCT02812524Phase 1
• Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before SurgeryActive, not recruitingNCT02812420Early Phase 1
• Study of Azacitidine and Durvalumab in Advanced Solid TumorsCompletedNCT02811497Phase 2
• Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast CancerCompletedNCT02802098Early Phase 1
• Nivolumab Plus Radiotherapy in Advanced MelanomaCompletedNCT02799901Phase 2
• Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic TumorsCompletedNCT02794571Phase 1
• Durvalumab in Pediatric and Adolescent PatientsCompletedNCT02793466Phase 1
• A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsCompletedNCT02791334Phase 1
• Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic MyelomaTerminatedNCT02784483Phase 1
• A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast CancerActive, not recruitingNCT02779751Phase 1
• Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)Status unknownNCT02779101Phase 2
• Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal CancersCompletedNCT02777710Phase 1
• Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell CarcinomaCompletedNCT02775812Phase 1
• Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1CompletedNCT02775292Phase 1
• Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and NeckActive, not recruitingNCT02769520Phase 2
• Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)Active, not recruitingNCT02767063Phase 1/2
• Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck CancerCompletedNCT02764593Phase 1
• Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell CarcinomaCompletedNCT02762006Phase 1
• Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)Status unknownNCT02758587Phase 1/2
• CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal TumorsTerminatedNCT02757391Phase 1
• A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingNCT02755272Phase 2
• Study of ONO-4538 in Gastric CancerCompletedNCT02746796Phase 2/3
• A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor SubjectsCompletedNCT02742935Phase 1
• A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced MelanomaCompletedNCT02738489Phase 1
• Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder CarcinomaCompletedNCT02736266Phase 2
• A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic CancerCompletedNCT02734160Phase 1
• Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung CancerCompletedNCT02733250Phase 1/2
• Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)Active, not recruitingNCT02726997Phase 1/2
• Pilot Study of Durvalumab and Vigil in Advanced Women's CancersCompletedNCT02725489Phase 2
• A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid TumorsCompletedNCT02722954Phase 1
• A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor SubjectsCompletedNCT02721589Phase 1
• Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic MelanomaWithdrawnNCT02719015Phase 1/2
• Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid TumorsActive, not recruitingNCT02717156Phase 2
• SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or SpineCompletedNCT02716948Phase 1
• Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) PatientsCompletedNCT02716272Phase 2
• Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid TumorsActive, not recruitingNCT02715284Phase 1
• A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural MesotheliomaTerminatedNCT02707666Phase 1
• Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCCCompletedNCT02707588Phase 2
• LOAd703 Oncolytic Virus Therapy for Pancreatic CancerCompletedNCT02705196Phase 1/2
• Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the EyeCompletedNCT02697630Phase 2
• Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung CancerActive, not recruitingNCT02696993Phase 1/2
• A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative SurgeryTerminatedNCT02691026Phase 2
• Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast CancerCompletedNCT02685059Phase 2
• Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)CompletedNCT02684292Phase 3
• Phase I Study of PDR001 in Patients With Advanced Malignancies.CompletedNCT02678260Phase 1
• Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy TrialActive, not recruitingNCT02678182Phase 2
• Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular LymphomaCompletedNCT02677155Phase 2
• Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic MelanomaCompletedNCT02676869Phase 1
• Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung CancerWithdrawnNCT02673814Phase 2
• A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced CancerTerminatedNCT02671955Phase 1
• National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
• A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)WithdrawnNCT02663258Phase 2
• Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain MetastasesCompletedNCT02662725Phase 2
• Preoperative MPDL3280A in Transitional Cell Carcinoma of the BladderCompletedNCT02662309Phase 2
• Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)CompletedNCT02658981Phase 1
• Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator PhenotypeActive, not recruitingNCT02658279Not applicable
• Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersCompletedNCT02655822Phase 1
• Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)WithdrawnNCT02653989Phase 2
• A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell MalignanciesCompletedNCT02651662Phase 1
• Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving TrastuzumabCompletedNCT02649686Phase 1
• Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent GlioblastomaTerminatedNCT02648633Phase 1
• Study of the Effects of Pembrolizumab in Patients With Advanced Solid TumorsActive, not recruitingNCT02644369Phase 2
• Vigil™ + Nivolumab in Advanced Non-Small Cell Lung CancerWithdrawnNCT02639234Phase 2
• Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic CancersCompletedNCT02639026Phase 1
• Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseCompletedNCT02636010Phase 2
• Phase I Dose Escalation Study for VIP152 in Patients With Advanced CancerCompletedNCT02635672Phase 1
• A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)Status unknownNCT02630368Phase 1/2
• Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or NivolumabCompletedNCT02628574Phase 1
• Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer PatientsCompletedNCT02628132Phase 1/2
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
• Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal MelanomaCompletedNCT02626962Phase 2
• Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney CancerCompletedNCT02626130Early Phase 1
• Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal AntibodiesCompletedNCT02626065Phase 4
• Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)TerminatedNCT02625961Phase 2

← Immune Checkpoint Inhibitors overview